Loading organizations...
Based in Albuquerque, New Mexico, Daisy Genomics develops a physics-based DNA and RNA sequencing platform utilizing proprietary spectroscopy and specialized chips for highly efficient, data-rich genomic analysis. The company's core technology supports advanced precision medicine applications, specifically enabling targeted cancer treatments and the early detection of epigenetic markers for various disease predispositions. Operating out of the local BioScience Center incubator, the seed-stage startup recently secured $2.5 million in a funding round led by institutional investors Cottonwood Technology Fund and Tramway Venture Partners. This newly raised capital will be deployed to scale local operations, advance their sequencing prototypes toward full commercialization, and expand strategic research partnerships with leading universities and clinical diagnostics firms across the industry. The enterprise aims to modernize traditional sequencing infrastructure for broader clinical applications. Daisy Genomics was founded in 2015 by Emily Milsovic.
Daisy Genomics has raised $2.5M across 1 funding round.
Daisy Genomics has raised $2.5M in total across 1 funding round.
Daisy Genomics has raised $2.5M in total across 1 funding round.
Daisy Genomics's investors include Cottonwood Technology Fund, Tramway Venture Partners, Wave Capital.
Daisy Genomics has raised $2.5M across 1 funding round. Most recently, it raised $2.5M Seed in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 17, 2025 | $2.5M Seed | — | Cottonwood Technology Fund, Tramway Venture Partners, Wave Capital | Announced |
